Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;29(1):3197-3212.
doi: 10.1080/10717544.2022.2132018.

A technical note on emerging combination approach involved in the onconanotherapeutics

Mohammad Kashif Iqubal  1   2 , Harsimran Kaur  3 , Shadab Md  4 , Nabil A Alhakamy  4 , Ashif Iqubal  5 , Javed Ali  2 , Sanjula Baboota  2
Affiliations
Review

A technical note on emerging combination approach involved in the onconanotherapeutics

Mohammad Kashif Iqubal et al. Drug Deliv. 2022 Dec.

Abstract

Cancer is the second cause of mortality worldwide, and the currently available conventional treatment approach is associated with serious side effects and poor clinical outcomes. Based on the outcome of the exploratory preclinical and clinical studies, it was found that therapeutic response increases multiple folds when anticancer drugs are used in combination. However, the conventional combination of anticancer drugs was associated with various limitations such as increased cost of treatment, systemic toxicity, drug resistance, and reduced pharmacokinetic attributes. Hence, attempts were made to formulate nanocarrier fabricated combinatorial drugs (NFCDs) to effectively manage and treat cancer. This approach offers several advantages, such as improved stability, lower drug exposure, targeted drug delivery, low side effects, and improved clinical outcome. Hence, in this review, first time, we have discussed the recent advancement and various types of nano carrier-based combinatorial drug delivery systems in a different type of cancer and highlighted the personalized combinatorial theranostic medicine as a futuristic anticancer treatment approach.

Keywords: Chemotherapy; dual-drug combination; immunotherapy; nanotechnology; personalized medicine.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1.
Figure 1.
The molecular mechanism of carcinogenesis.
Figure 2.
Figure 2.
Brief classification of nanocarriers.
Figure 3.
Figure 3.
The classical example of nanocarrier based combinational drug delivery in oncotherapy. (A) and (B) showing different types of architects of noncarriers used and mechanism of combinational drug delivery as potent anticancer therapy (Li et al., ; Zhao et al., 2019).
See this image and copyright information in PMC

References

    1. Al-Lazikani B, Banerji U, Workman P. (2012). Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 30:679–92. 10.1038/nbt.2284 - DOI - PubMed
    1. Alimoradi H, Greish K, Barzegar-Fallah A, et al. (2018). Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity. IJN 13:7771–87. 10.2147/IJN.S187089 - DOI - PMC - PubMed
    1. Alrumaihi F, Khan MA, Babiker AY, et al. (2022a). Lipid-based nanoparticle formulation of diallyl trisulfide chemosensitizes the growth inhibitory activity of doxorubicin in colorectal cancer model: a novel in vitro, in vivo and in silico analysis. Molecules 27:2192. 10.3390/molecules27072192 - DOI - PMC - PubMed
    1. Alrumaihi F, Khan MA, Babiker AY, et al. (2022b). The effect of liposomal diallyl disulfide and oxaliplatin on proliferation of colorectal cancer cells: in vitro and in silico analysis. Pharmaceutics 14:236. 10.3390/pharmaceutics14020236 - DOI - PMC - PubMed
    1. Anajafi T, Yu J, Sedigh A, et al. (2017). Nuclear localizing peptide-conjugated, redox-sensitive polymersomes for delivering curcumin and doxorubicin to pancreatic cancer microtumors. Mol Pharm 14:1916–28. 10.1021/acs.molpharmaceut.7b00014 - DOI - PubMed

Substances